0.1003
price up icon4.59%   0.0044
after-market 시간 외 거래: .10 -0.0003 -0.30%
loading
전일 마감가:
$0.0959
열려 있는:
$0.0928
하루 거래량:
9.26M
Relative Volume:
0.26
시가총액:
$13.89M
수익:
-
순이익/손실:
$-27.39M
주가수익비율:
-0.0597
EPS:
-1.6803
순현금흐름:
$-2.09M
1주 성능:
-4.02%
1개월 성능:
-5.11%
6개월 성능:
-68.45%
1년 성능:
+0.00%
1일 변동 폭
Value
$0.0928
$0.1008
1주일 범위
Value
$0.092
$0.1144
52주 변동 폭
Value
$0.0709
$2.10

Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile

Name
명칭
Aspire Biopharma Holdings Inc
Name
전화
561-704-8527
Name
주소
23150 FASHION DRIVE, SUITE 232, ESTERO
Name
직원
0
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
ASBP's Discussions on Twitter

ASBP을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ASBP
Aspire Biopharma Holdings Inc
0.1003 13.28M 0 -27.39M -2.09M -1.6803
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.38 114.05B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
748.71 78.80B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
396.04 51.80B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
847.05 53.08B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.55 42.33B 447.02M -1.18B -906.14M -6.1812

Aspire Biopharma Holdings Inc 주식(ASBP)의 최신 뉴스

pulisher
04:05 AM

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

04:05 AM
pulisher
08:32 AM

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine - ACCESS Newswire

08:32 AM
pulisher
08:30 AM

How a 100-mile ultra-runner gets 'instant' energy from sublingual caffeine - Stock Titan

08:30 AM
pulisher
12:53 PM

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Asbury Park Press

12:53 PM
pulisher
Dec 16, 2025

Aspire Biopharma Provides Q3 2025 Business Update - Palm Beach Daily News

Dec 16, 2025
pulisher
Dec 15, 2025

Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching - ts2.tech

Dec 15, 2025
pulisher
Dec 14, 2025

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Peoria Journal Star

Dec 14, 2025
pulisher
Dec 13, 2025

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance With Continued Listing Requirements - 富途牛牛

Dec 13, 2025
pulisher
Dec 13, 2025

Aspire Biopharma Hldgs (ASBP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 13, 2025
pulisher
Dec 12, 2025

Aspire Biopharma gets Nasdaq extension to meet listing requirements By Investing.com - Investing.com Nigeria

Dec 12, 2025
pulisher
Dec 12, 2025

Aspire Biopharma gets Nasdaq extension to meet listing requirements - Investing.com

Dec 12, 2025
pulisher
Dec 12, 2025

POWP ACQUPAR : Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - marketscreener.com

Dec 12, 2025
pulisher
Dec 12, 2025

Aspire Biopharma (Nasdaq: ASBP) gains extension, moves to Nasdaq Capital Market - Stock Titan

Dec 12, 2025
pulisher
Dec 07, 2025

Aspire Biopharma’s BUZZ BOMB Shows Promising Initial Feedback - MSN

Dec 07, 2025
pulisher
Dec 06, 2025

Aspire Biopharma Hldgs (ASBPW) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 06, 2025
pulisher
Dec 06, 2025

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Victorville Daily Press

Dec 06, 2025
pulisher
Dec 05, 2025

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Alliance Review

Dec 05, 2025
pulisher
Dec 04, 2025

Aspire Biopharma advances sublingual drug delivery technology By Investing.com - Investing.com Nigeria

Dec 04, 2025
pulisher
Dec 04, 2025

Aspire Biopharma advances sublingual drug delivery technology - Investing.com

Dec 04, 2025
pulisher
Dec 04, 2025

Aspire Biopharma (Nasdaq: ASBP) targets H1 2026 NDA after fast-acting aspirin data - Stock Titan

Dec 04, 2025

Aspire Biopharma Holdings Inc (ASBP) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$38.43
price up icon 0.31%
$97.31
price down icon 0.33%
$31.50
price down icon 0.66%
$91.46
price down icon 0.15%
biotechnology ONC
$307.02
price up icon 0.32%
$166.55
price down icon 16.08%
자본화:     |  볼륨(24시간):